Tier 2 — strong

Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers

Kyoung-Ah Kim, Pil-Whan Park, Ji-Young Park
European journal of clinical pharmacology 2009 65(6):609

Bibliography

PubMed
PMID 19221726
DOI
10.1007/s00228-009-0627-6
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignPlacebo-controlled human drug-interaction study
ModelHuman intervention research
Sample12 healthy volunteers
InterventionQuercetin 500 mg three times daily; fexofenadine 60 mg on day 7
Duration7 days
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2009, this source examined safety, interactions and special populations. Design: Placebo-controlled human drug-interaction study. Sample/model: 12 healthy volunteers. The exposure or intervention was Quercetin 500 mg three times daily; fexofenadine 60 mg on day 7. Follow-up or treatment period: 7 days.

Fexofenadine exposure rose by approximately 55% and peak concentration by approximately 68% during quercetin treatment.

Small high-dose pharmacokinetic study. It demonstrates an interaction under the tested conditions but not a predictable magnitude for every antihistamine or transporter substrate.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Interactions: Medicines, Evidence and Precautions. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Fexofenadine exposure rose by approximately 55% and peak concentration by approximately 68% during quercetin treatment.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Quercetin 500 mg three times daily; fexofenadine 60 mg on day 7; 7 days.

What this study can and cannot tell us

  • Small high-dose pharmacokinetic study. It demonstrates an interaction under the tested conditions but not a predictable magnitude for every antihistamine or transporter substrate.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia
Parinda A Mehta et al. · Blood advances · 2025
Tier 2
Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease
Meilan K Han et al. · BMJ open respiratory research · 2020
Tier 2
Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin
Antonella Riva et al. · Minerva cardioangiologica · 2019

Citation network

Articles citing this research paper

4 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology